Research ArticleCancer
The Receptor AXL Diversifies EGFR Signaling and Limits the Response to EGFR-Targeted Inhibitors in Triple-Negative Breast Cancer Cells
- Aaron S. Meyer1,2,
- Miles A. Miller1,
- Frank B. Gertler2,3, and
- Douglas A. Lauffenburger1,2,3,*
- 1Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
- 2David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
- 3Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
- ↵*Corresponding author. E-mail: lauffen{at}mit.edu
See allHide authors and affiliations
Science Signaling 06 Aug 2013:
Vol. 6, Issue 287, pp. ra66
DOI: 10.1126/scisignal.2004155
